Alogliptin after acute coronary syndrome in patients with type 2 diabetes
- White, William B.
- Cannon, Christopher P.
- Heller, Simon R.
- Nissen, Steven E.
- Bergenstal, Richard M.
- Bakris, George L.
- Perez, Alfonso T.
- Fleck, Penny R.
- Mehta, Cyrus R.
- Kupfer, Stuart
- Wilson, Craig
- Cushman, William C.
- Zannad, Faiez
DOIAbstract
BackgroundTo assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome
Add to ORKG